rivaroxaban / Generic mfg. - LARVOL DELTA

Safety and efficacy of escalating antithrombotic therapy after lower extremity revascularization for chronic limb threatening ischemia. (PubMed, J Vasc Surg) - "Escalation of antithrombotic therapy beyond SAPT after first-time lower extremity revascularization for CLTI is associated with higher bleeding risk, and triple therapy with lower survival, possibly reflecting the vulnerability of frailer patients less able to tolerate bleeding complications. No differences were observed in MI, stroke, patency, or MALE, underscoring the challenge of balancing limb-related outcomes with bleeding risk. Careful monitoring, individualized risk stratification, and shared decision-making remain essential. Larger studies are needed to further define the relative efficacy and safety of intensified antithrombotic regimens."

Journal • Atrial Fibrillation • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Coronary Artery Disease • Gastroenterology • Hematological Disorders • Hypertension • Peripheral Arterial Disease

Real-World Evidence in the First Round of the US Inflation Reduction Act Drug Price Negotiations: A Citation Analysis of CMS Maximum Fair Price Explanation Documents. (PubMed, Value Health) - "These findings underscore the need for greater transparency and consistent methodological standards for evaluating RWE, aligning Medicare's process more closely with international health technology assessment practices."

HEOR • Journal • Real-world evidence

Chronic pulmonary aspergillosis and pulmonary embolism/venous thromboembolism: a case series and systematic review of the literature. (PubMed, Ther Adv Infect Dis) - "All patients received itraconazole and anticoagulation with rivaroxaban. CPA may coexist with PE/DVT due to fungal angioinvasion, chronic inflammation, or immobilization from advanced lung disease. Management requires individualized balancing of antifungal and anticoagulation therapy, with heightened vigilance for bleeding."

Journal • Cardiovascular • Chronic Obstructive Pulmonary Disease • Human Immunodeficiency Virus • Hypertension • Immunology • Infectious Disease • Inflammation • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Septic Shock • Tuberculosis • Venous Thromboembolism • CD4

BEYOND CHADS2-VASC: QUESTIONING SYSTEMIC ANTICOAGULATION IN ADVANCED CHRONIC RENAL DISEASE WITH AURICULAR FIBRILATION (ISN-WCN 2026) - "Even the most recent clinical guidelines recommend individualized use of these scales in this subgroup of patients.Regarding treatment, vitamin K antagonist anticoagulants, such as warfarin or acenocoumarol, have historically been the most widely used drugs...In addition, INR control is especially complex in these patients, with increased risk of overanticoagulation.Direct-acting oral anticoagulants, such as apixaban, edoxaban, rivaroxaban and dabigatran, have demonstrated a better safety profile in certain contexts, with lower bleeding risk than vitamin K antagonist anticoagulants...This scale allows a stratification more adjusted to the renal profile and contributes to reduce unnecessary exposure to anticoagulant treatments with significant bleeding risk.It is necessary to promote a multidisciplinary and individualized approach in the assessment of thromboembolic and bleeding risk in this population, integrating the nephrologist in the therapeutic decision-making..."

Metastases • Atrial Fibrillation • Calciphylaxis • Cerebral Hemorrhage • Chronic Kidney Disease • CNS Disorders • Diabetes • Diabetic Nephropathy • Hematological Disorders • Hypertension • Metabolic Disorders • Nephrology • Peripheral Arterial Disease • Pulmonary Arterial Hypertension • Rare Diseases • Renal Disease

ASSOCIATION BETWEEN URINARY TUBULAR INJURY MARKERS AND BLEEDING RISK IN PATIENTS WITH ATRIAL FIBRILLATION AND CHRONIC KIDNEY DISEASE RECEIVING RIVAROXABAN (ISN-WCN 2026) - "Of the bleeding, bruises were common in 52 patients (19%), nosebleeds were found in 22 patients (8.3%), bleeding from minor wounds was noted in 12 patients (4.3%), muscle hematomas were found in 6 patients (2.2%), bleeding from the oral cavity was found in 6 patients (2.2%), and hemorrhoidal bleeding was diagnosed in 2 patients (0.75%). The levels of NGAL and KIM-1 in urine in patients with AF and CKD in group 1 (5.6 ng/ml and 0.69 ng/ml, respectively) were statistically significantly higher compared to patients in group 2 (4.2 ng/ml (p=0.039) and 0.39 ng/ml (p=0.019).Conclusion Our study results indicate the presence of a statistically significant association between the presence of bleeding in patients with AF and CKD stages 3–4 receiving rivaroxaban with the level of tubular damage markers KIM-1 and NGAL in urine."

Clinical • Atrial Fibrillation • Cardiovascular • Chronic Kidney Disease • Gastroenterology • Nephrology • Renal Disease • KIM1 • LCN2

ANTICOAGULANT - ASSOCIATED ACUTE KIDNEY INJURY: A PHARMACOVIGILANCE ANALYSIS BASED ON FDA ADVERSE EVENT REPORTING SYSTEM (ISN-WCN 2026) - "A).Warfarin had stable low reports, while newer oral anticoagulants (NOACs) showed dramatic trends: Apixaban peaked over 20,000 around 2021, Rivaroxaban near 20,000 in 2015, Dabigatran over 11,000 in 2012. Drugs like Argatroban, Bivalirudin, and Dalteparin had consistently low reports (Fig...Results show heterogeneity in renal ADRs; Fondaparinux and Apixaban signal specific toxicities. Findings can guide pharmacovigilance and clinical decisions for renal risk patients."

Adverse events • Acute Kidney Injury • Nephrology • Renal Disease • ROR1

Factor XI Inhibitors in Atrial Fibrillation: Insights and Implications from Recent Trials. (PubMed, Adv Ther) - "For example abelacimab, an anti-FXI monoclonal antibody, demonstrated superior safety with lower bleeding rates when compared to rivaroxaban in patients with AF...However, the OCEANIC-AF trial, which studied the small molecule FXI inhibitor asundexian, was terminated early due to lack of efficacy as there was an increased rate of stroke and systematic embolism compared to the DOAC apixaban, raising new concerns about the utility of targeting FXI. However, many FXI inhibitors are currently undergoing phase 3 trials, and as such the true efficacy of the full class of FXI inhibitors remains to be elucidated. This review aims to provide a comprehensive synopsis of the landscape of FXI inhibitors in development for AF, their advantages, challenges, and known utility with a focus on how they may be applied to future anticoagulation therapy for AF."

Journal • Review • Atrial Fibrillation • Cardiovascular

Characteristics and outcomes of patients with diabetes mellitus selected for dual pathway inhibition in clinical practice: The XATOA registry. (PubMed, Vasc Med) - "Patients with DM with CVD are at significantly high cardiovascular risk, and those with PAD appear to be undertreated. Real-world outcomes observed in the XATOA registry are consistent with randomized trial data, supporting the benefit of DPI in this high-risk population."

Journal • Atherosclerosis • Cardiovascular • Coronary Artery Disease • Diabetes • Metabolic Disorders • Peripheral Arterial Disease

Estimating real-world treatment effects in the presence of measurement error and sparse outcome data using propensity score methods. (PubMed, Front Pharmacol) - "The motivational example for this study was the assessment of the treatment effect of the novel oral anti-coagulant Rivaroxaban compared with the previous standard treatment Warfarin for the prevention of future stroke in patients with atrial fibrillation. This study showed that PS methods proposed in the literature may not all perform well for individual datasets. The findings produced recommendations for using PS methods in the estimation of real-world treatment effect when the covariate measurement error and sparse outcome data are present."

HEOR • Journal • Real-world evidence • Atrial Fibrillation • Cardiovascular

Population pharmacokinetics of rivaroxaban after transjugular intrahepatic portosystemic shunt. (PubMed, Eur J Clin Pharmacol) - No abstract available

Journal • PK/PD data

Analysis of the clinical characteristics of direct oral anticoagulants-associated atraumatic splenic rupture. (PubMed, Front Pharmacol) - "Among them, apixaban (n = 17) was the most common DOAC, followed by rivaroxaban (n = 8) and dabigatran (n = 2), with atrial fibrillation (81.5%, n = 22) being the primary indication. ASR is a potentially life-threatening but preventable DOAC complication. Early recognition-particularly in elderly patients with comorbidities and polypharmacy-and urgent imaging for abdominal pain are crucial for improving clinical outcomes."

Journal • Atrial Fibrillation • Cardiovascular • Coronary Artery Disease • Heart Failure • Hypertension • Infectious Disease • Oncology • Pain

TRACK: Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease (clinicaltrials.gov) - P3 | N=1753 | Completed | Sponsor: The George Institute | Active, not recruiting ➔ Completed

Trial completion • Cardiovascular • Chronic Kidney Disease • Nephrology • Renal Disease

Warfarin use: how many of you in CKD5D have stopped using it and now use Apixaban or Rivaroxaban (ERA 2026) - No abstract available

Cardiovascular • Chronic Kidney Disease

Rivaroxaban, colchicine and famotidine/loratadine with integrated clinical care for Long COVID, a multi-site, open-label randomised controlled trial (ESCMID Global 2026) - No abstract available

Clinical • Late-breaking abstract • Novel Coronavirus Disease

Advancing Point-of-Care Analysis: The Future of Thromboelastographic DOAC-Detection: A Systematic Review. (PubMed, Semin Thromb Hemost) - "For direct factor Xa inhibitors-rivaroxaban, apixaban, and edoxaban-modified assays using Russell's Viper Venom, factor Xa-based reagents, and low-tissue-factor activation showed variable but generally good correlations with drug levels (r = 0.571-0.969). Ecarin-based tests appear reliable for dabigatran, while Russell's Viper Venom and low-tissue-factor approaches may enable detection of direct factor Xa inhibitors. However, further clinical validation and standardization are required before routine implementation."

Journal • Cardiovascular • Ischemic stroke

Safety and efficacy of direct oral anticoagulants in pediatric oncology patients: real-world data from two quaternary care pediatric centers. (PubMed, Res Pract Thromb Haemost) - "Rivaroxaban and apixaban were used in 55% and 45% of patients, respectively. No deaths were attributed to thrombosis or anticoagulant-related bleeding. Rates of recurrent/progressive thrombosis and clinically relevant bleeding in our cohort of children with cancer-associated thrombosis are higher than those reported in previous studies, highlighting the importance of real-world data."

Journal • Real-world evidence • Cardiovascular • Hematological Disorders • Oncology • Oral Cancer • Pediatrics • Thrombosis • Venous Thromboembolism

Upadacitinib in refractory ulcerative colitis patients with high thromboembolic risk: two case reports. (PubMed, Front Immunol) - "The current case report describes two UC patients with high thromboembolic risk successfully treated with upadacitinib and rivaroxaban. The two patients reported increased stool frequency, decreased stool consistency, abdominal pain and hematochezia, both of whom had experienced mesalazine, corticosteroids, vedolizumab and infliximab, all failed to induce clinical remission...No thromboembolic events or other adverse effects have been observed to date. Our case report suggests that concurrent use of anticoagulation with upadacitinib may represent a safe and valuable strategy for treating refractory UC with high thromboembolic risk."

Journal • Cardiovascular • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Immunology • Inflammatory Bowel Disease • Pain • Thrombosis • Ulcerative Colitis

Safety and efficacy of rivaroxaban versus warfarin in atrial fibrillation with stage 4 to 5 chronic kidney disease including dialysis. (PubMed, Res Pract Thromb Haemost) - "In patients with AF and advanced CKD including dialysis, rivaroxaban may be associated with improved efficacy and safety compared with warfarin. However, heterogeneity in CKD stages and off-label dosing practices necessitate prospective randomized trials to establish definitive treatment recommendations."

Journal • Atrial Fibrillation • Cardiovascular • Cerebral Hemorrhage • Chronic Kidney Disease • CNS Disorders • Gastroenterology • Hematological Disorders • Nephrology • Renal Disease

EvaluaTion of Clinical and laboratory outcomes of Rivaroxaban in short Bowel syndrome patients dEpending on Long term parenteral nutrition: a prospective cohort study (TINCRBEL study) (clinicaltrialsregister.eu) - P4 | N=24 | Recruiting | Sponsor: Amsterdam UMC Stichting | Not yet recruiting ➔ Recruiting

Enrollment open • Gastrointestinal Disorder • Short Bowel Syndrome

CORONARY ARTERY ECTASIA: DIVERSE PATHOPHYSIOLOGY AND IMPLICATIONS FOR TAILORED MANAGEMENT (ACC 2026) - "He was treated with statin, ezetimibe, aspirin, rivaroxaban, with plan to initiate evolocumab. Optimal care of CAE requires thoughtful evaluation and individualized therapy."

Atherosclerosis • Cardiovascular • Dyslipidemia • Metabolic Disorders • Myocardial Infarction

Network analysis-guided drug repurposing: IGF1R as a novel melanoma target and therapeutic potential of dapagliflozin. (PubMed, Daru) - "Virtual screening (DrugBank) identified Dapagliflozin and Rivaroxaban, which were further evaluated by molecular dynamics (MD) simulations, binding free energy (MM/GBSA) calculations, and in vitro cytotoxicity using the MTT assay on B16F10 melanoma cells. Computational analyses predicted favorable binding for Dapagliflozin to IGF1R, and subsequent in vitro experiments confirmed its moderate cytotoxic effects on melanoma cells, supporting its further investigation as a potential repurposed therapeutic agent for melanoma. The online version contains supplementary material available at 10.1007/s40199-026-00598-x."

Journal • Cutaneous Melanoma • Melanoma • Oncology • Solid Tumor • IGF1R

Relevance and limitations of clinical follow-up in a pharmacokinetic study on direct oral anticoagulants. (PubMed, Front Pharmacol) - "In this real-world cohort, apixaban and rivaroxaban plasma concentrations were not associated with clinical outcomes. While highlighting the limitations of analyzing clinical outcomes within the framework of a pharmacokinetic study, these data are informative for future meta-analyses aimed at minimizing publication bias from neutral results."

Journal • PK/PD data • Cardiovascular • Ischemic stroke • Venous Thromboembolism

Safety of prothrombin complex concentrate for emergency surgery according to the oral factor Xa inhibitor level. (PubMed, Thromb Haemost) - "Results PCC at a median dose of 2000 units (interquartile range, 2000-2000) was administered to 227 patients on apixaban (143; 63%), rivaroxaban (72; 32%), or edoxaban (12;5%). Conclusion The risk of thromboembolism after 4F-PCC in patients on XaI and emergency surgery/invasive procedures appears to be similar among patients with preoperative XaI levels that are high, low or not measured. This information might be helpful in settings where rapid anti Xa testing is unavailable."

Journal • Cardiovascular • Venous Thromboembolism

Real-world use of rivaroxaban for primary thromboprophylaxis and cardiac thrombosis treatment in congenital and acquired heart disease: a prospective cohort study. (PubMed, Sci Rep) - No abstract available

Journal • Real-world evidence • Cardiovascular • Heart Failure • Hematological Disorders • Pediatrics • Thrombosis

Efficacy and Safety of DOACs in Patients with Atrial Fibrillation and History of Falls or Risk of Falls: The Liverpool AF-Falls Project. A Systematic Review and Bayesian Network Meta-analysis. (PubMed, Drugs Aging) - "DOACs appear to have different efficacy and safety profiles and overall are preferable over VKAs in patients with AF with a history or risk of falls. Because of bias, further research is warranted."

Journal • Retrospective data • Review • Atrial Fibrillation • Cardiovascular